Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + gemcitabine + cisplatin with transarterial embolization for unresectable intrahepatic cholangiocarcinoma
ChiCTR2400082981Phase 2Recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, gemcitabine and cisplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective response rate. Started Apr 2024; status: recruiting.
02
Drugs
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2400082981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082981.